scholarly journals Templated Three-Dimensional Engineered Bone Matrix as a Model for Breast Cancer Osteolytic Bone Metastasis Process

2021 ◽  
Vol Volume 16 ◽  
pp. 8391-8403
Author(s):  
Manman Sun ◽  
Ke Huang ◽  
Xueshi Luo ◽  
Hong Li
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Bone Matrix ◽  
Three Dimensional ◽  
Osteolytic Bone Metastasis

Biological and Toxicological Evaluation of N-(4methyl-phenyl)-4-methylphthalimide on Bone Cancer in Mice

2019 ◽  
Vol 19 (5) ◽  
pp. 667-676
Author(s):  
José R. Santin ◽  
Gislaine F. da Silva ◽  
Maria V.D. Pastor ◽  
Milena F. Broering ◽  
Roberta Nunes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
In Silico ◽  
Bone Matrix ◽  
Micronucleus Assay ◽  
Repeated Treatment ◽  
Toxicological Evaluation ◽  
Toxicological Analysis ◽  
Breast Cancer Bone Metastasis

Background: It was recently demonstrated that the phthalimide N-(4-methyl-phenyl)-4- methylphthalimide (MPMPH-1) has important effects against acute and chronic pain in mice, with a mechanism of action correlated to adenylyl cyclase inhibition. Furthermore, it was also demonstrated that phthalimide derivatives presented antiproliferative and anti-tumor effects. Considering the literature data, the present study evaluated the effects of MPMPH-1 on breast cancer bone metastasis and correlated painful symptom, and provided additional toxicological information about the compound and its possible metabolites. Methods: In silico toxicological analysis was supported by in vitro and in vivo experiments to demonstrate the anti-tumor and anti-hypersensitivity effects of the compound. Results: The data obtained with the in silico toxicological analysis demonstrated that MPMPH-1 has mutagenic potential, with a low to moderate level of confidence. The mutagenicity potential was in vivo confirmed by micronucleus assay. MPMPH-1 treatments in the breast cancer bone metastasis model were able to prevent the osteoclastic resorption of bone matrix. Regarding cartilage, degradation was considerably reduced within the zoledronic acid group, while in MPMPH-1, chondrocyte multiplication was observed in random areas, suggesting bone regeneration. Additionally, the repeated treatment of mice with MPMPH-1 (10 mg/kg, i.p.), once a day for up to 36 days, significantly reduces the hypersensitivity in animals with breast cancer bone metastasis. Conclusion: Together, the data herein obtained show that MPMPH-1 is relatively safe, and significantly control the cancer growth, allied to the reduction in bone reabsorption and stimulation of bone and cartilage regeneration. MPMPH-1 effects may be linked, at least in part, to the ability of the compound to interfere with adenylylcyclase pathway activation.

Osteolytic bone metastasis in breast cancer

1994 ◽  
Vol 32 (1) ◽  
pp. 73-84 ◽  
Author(s):  
Toshiyuki Yoneda ◽  
Akira Sasaki ◽  
Gregory R. Mundy
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Osteolytic Bone Metastasis

scholarly journals Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Jin Liu ◽  
Defang Li ◽  
Lei Dang ◽  
Chao Liang ◽  
Baosheng Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Osteolytic Bone Metastasis

scholarly journals Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer

2020 ◽  
Vol 61 (3) ◽  
pp. 494-498
Author(s):  
Hidekazu Tanaka ◽  
Chiyoko Makita ◽  
Yuki Manabe ◽  
Miki Kajima ◽  
Katsuya Matsuyama ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Progressive Disease ◽  
Overall Survival Rate ◽  
Local Response ◽  
Osteolytic Bone Metastasis ◽  
Rate Of Response

Abstract Bone-modifying agents (BMAs) are frequently used for the treatment of bone metastases. Both BMA and radiation therapy (RT) are effective; however, there are few studies that have evaluated the efficacy of the combination treatment. We evaluated the effectiveness of RT + BMA in breast cancer-induced osteolytic bone metastasis as compared to BMA alone. A total of 43 lesions in 25 patients were evaluated. The median follow-up period was 18 (range, 2–90) months. None of the lesions was treated with chemotherapy or molecular targeted drugs during the follow-up period for evaluating the local response. Patients with complete or partial response were considered as responders, while those with stable or progressive disease were considered as non-responders. The rate of response with RT + BMA was significantly higher than that with BMA alone (P = 0.001). The cumulative incidence rate of response at 6 months was 54.4% in the RT + BMA group and 27.5% in the BMA alone group. The median time to response was 4 (range, 2–11) months in the RT + BMA group and 6 (range, 4–16) months in the BMA alone group. The overall survival rate in the responder group (83.1% at 1 year) was significantly higher than that in the non-responder group (37.5% at 1 year) (P = 0.029). In conclusion, RT combined with BMA was found to be more effective than BMA alone for the treatment of osteolytic bone metastasis, which thereby improves the prognosis.

Immunization With RANKL Inhibits Osteolytic Bone Metastasis in Breast Cancer

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Bora Kim ◽  
Yong Jin Cho ◽  
Mineon Park ◽  
Wonbong Lim
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Osteolytic Bone Metastasis

NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF

2006 ◽  
Vol 13 (1) ◽  
pp. 62-69 ◽  
Author(s):  
Bae Keun Park ◽  
Honglai Zhang ◽  
Qinghua Zeng ◽  
Jinlu Dai ◽  
Evan T Keller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Osteolytic Bone Metastasis ◽  
Gm Csf
Sign in / Sign up

Export Citation Format

Share Document